Clinical Trial Update: Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating bomedemstat versus hydroxyurea for essential thrombocythemia is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia

Drugs mentioned

• Bomedemstat (bomedemstat)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Essential Thrombocythemia | Phase 3 | Status: RECRUITING